At the news
? BULLISHIMPACT 7/10 6-K filed Sep 8, 2026 at 06:29 ET
AstraZeneca announced FDA accelerated approval of Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for 1st-line advanced HR-positive, HER2-negative breast cancer with an emergent ESR1 mutation. The approval, based on the SERENA-6 Phase III trial showing a 56% reduction in the risk of disease progression or death, expands AstraZeneca's breast cancer portfolio and represents the company's fourth FDA approval in breast cancer this year. This is a significant commercial catalyst for a large-market indication, though the accelerated approval pathway and immature overall survival data introduce some regulatory and competitive uncertainty.
- FDA accelerated approval of Etcamah (camizestrant) + CDK4/6 inhibitor for 1st-line advanced HR+/HER2- breast cancer with emergent ESR1 mutation.
- Approval based on SERENA-6 Phase III trial: 56% reduction in risk of disease progression or death (HR 0.44; p<0.00001; median PFS 16.0 vs 9.2 months).
- Statistically significant PFS2 benefit: 25.7 vs 19.1 months (HR 0.63; p=0.00373).
- OS data immature but trending in favor of Etcamah (HR 0.87; 95% CI 0.57-1.30).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access